Preclinical data from TP53-inactivated mouse models overexpressing JAK2V617F suggest that the combination of this sole abnormality in a JAK2V617F-overexpressing cell could be sufficient to cause acute transformation in 1.5 to 4 months [14, 15], but during the MPN phase development, the MPN phenotype of JAK2V617F/Trp53−/− mice does not seem to be highly different from the phenotype of JAK2V617F-only mice. The gene discussed is TP53; the disease is myeloproliferative disorder.